Key result
Anemia in patients undergoing percutaneous coronary intervention was associated with a significantly higher risk of long-term composite ischemic events (OR 1.95) and long-term bleeding events (OR 2.89).
Why the study?
Does anemia increase the risk of long-term ischemic and bleeding events in patients undergoing percutaneous coronary intervention?
Meta-Analysis (n=68,528)
Yes
Does anemia increase the risk of long-term ischemic and bleeding events in patients undergoing percutaneous coronary intervention?
Odds Ratio: 1.95 (95% CI 1.21–3.14)
p-value: p=<0.01
Anemia is a significant predictor of both long-term ischemic and bleeding events, as well as mortality and MACE, in patients undergoing percutaneous coronary intervention.
Anemia may inform post-PCI risk stratification; extends meta-analytic support for the association but leaves open whether correction improves outcomes.
BACKGROUND: Data focused on the ischemic events and bleeding events are still limited. We systematically reviewed the current available literature to investigate whether anemia increase incidence of long-term ischemic events and long-term bleeding events in patients undergoing PCI. METHODS: PubMed and Embase were searched for case-control studies regarding the impact of anemia on long-term outcomes in patients undergoing percutaneous coronary intervention (PCI). The primary outcome was long-term ischemic events and long-term bleeding events. Mantel-Haenszel method with random effects model or fixed effects model was used to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: Seventeen studies involving 68,528 patients (17,123 anemic patients and 51,405 non-anemic patients) were included. Pooled analysis suggested that anemic patients were at higher risk for long-term composite ischemic events (OR: 1.95, 95% CI, 1.21-3.14, P<0.01, I(2)=84%), long-term reinfarction (0R: 1.63, 95% CI, 1.16-2.28, P<0.01, I(2)=82%) and long-term bleeding events (OR: 2.89, 95% CI, 1.68-4.98, P<0.001, I(2)=89%). Anemia was also associated with long-term mortality (OR: 3.20, 95% CI, 2.72-3.75, P<0.01, I(2)=65%) and major adverse cardiac events (MACE) (OR: 2.06, 95% CI, 1.48-2.86, P<0.01, I(2)=91%). CONCLUSIONS: Anemic patients undergoing PCI are at higher risk for both long-term ischemic events and bleeding events, and also at higher risk for long-term mortality and MACE. There's a need for further clarification and consistency regarding dosage, timing and duration of antithrombotic therapy for the prevention of ischemic events and bleeding events in anemic patients.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2015) conducted a meta-analysis in Patients undergoing percutaneous coronary intervention (PCI) (n=68,528). Anemia vs. Non-anemic patients was evaluated on Long-term composite ischemic events (OR 1.95, 95% CI 1.21-3.14, p=<0.01). Anemia in patients undergoing percutaneous coronary intervention was associated with a significantly higher risk of long-term composite ischemic events (OR 1.95) and long-term bleeding events (OR 2.89).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: